Takeda Pharmaceutical (TAK) Invested Capital (2018 - 2026)

Takeda Pharmaceutical's Invested Capital history runs 9 years deep, the most recent figure standing at $31.1 billion for Q1 2026.

• On a quarterly basis, Invested Capital rose 5.18% year-over-year to $31.1 billion in Q1 2026; TTM through Mar 2026 was $117.0 billion, a 4.59% decrease from a year earlier, with the FY2026 full-year figure at $32.4 billion, up 9.41% from the prior year.
• Invested Capital climbed to $31.1 billion in Q1 2026 per TAK's latest filing, from $27.7 billion in the prior quarter.
• Across five years, Invested Capital topped out at $37.4 billion in Q1 2022 and bottomed at $27.7 billion in Q4 2022.
• The 5-year median for Invested Capital is $30.5 billion (2023), against an average of $30.9 billion.
• Across the five-year window, Invested Capital dropped 25.57% in 2022 and climbed 6.53% in 2024, its largest moves.
• Year by year, Invested Capital stood at $27.7 billion in 2022, then grew by 4.83% to $29.0 billion in 2023, then rose by 6.53% to $30.9 billion in 2024, then slipped by 10.34% to $27.7 billion in 2025, then increased by 12.19% to $31.1 billion in 2026.
• Per Business Quant, the three latest TAK Invested Capital figures stand at $31.1 billion (Q1 2026), $27.7 billion (Q4 2025), and $29.5 billion (Q3 2025).